Filing Flows › Exelixis (EXEL) › R&D spending
Exelixis (EXEL) R&D spending by quarter
Exelixis' R&D spending was $209M in Q3 2026 (third quarter 2026), -1% from Q2 2026. Over the last 7 quarters it ranged from $199M (Q3 2025) to $213M (Q4 2025).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $209M | -1% | +5% |
| Q2 2026 | $212M | +6% | +6% |
| Q1 2026 | $200M | -6% | -6% |
| Q4 2025 | $213M | +7% | — |
| Q3 2025 | $199M | -0.6% | — |
| Q2 2025 | $200M | -6% | — |
| Q1 2025 | $212M | — | — |
Q3 2026 at a glance
Exelixis, Q3 2026: revenue $659M (+10% year over year), operating margin 40.8%, net earnings $218M, operating cash flow $280M. The chart follows the revenue to costs, profit and cash.
Questions
What is Exelixis' R&D spending?
Exelixis' R&D spending was $209M in Q3 2026 (third quarter 2026), -1% from Q2 2026.
How has Exelixis' R&D spending changed?
Over the last 7 quarters it ranged from $199M (Q3 2025) to $213M (Q4 2025).